{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:08:37Z","timestamp":1790273317642,"version":"4.1.0"},"reference-count":50,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background<\/jats:title>\n While the prognosis is generally good for hormone receptor\u2013positive (HR+), human epidermal growth factor\u2013negative (HER2\u2013) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and\/or pathologic features experience recurrence.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n This retrospective cohort study was designed to estimate the proportion of BC patients meeting the high-risk criteria used in monarchE, a phase III study of abemaciclib, and to describe the characteristics, survival, and disease recurrence in a Danish patient population.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The study cohort included all women with BC diagnosis registered in the Danish Breast Cancer Cooperative Group registry, and lumpectomy or mastectomy performed between January 1, 2010, and December 31, 2019. The patient characteristics and survival outcomes were compared between high-risk patients (\u22654 positive lymph nodes or 1-3 positive nodes and grade 3 and\/or primary tumor size \u22655 cm), low\/moderate-risk patients, and patients with triple-negative EBC (TNBC).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 13.0% of the HR+, HER2\u2013 EBC patients met the high-risk criteria. Five-year invasive disease-free survival (IDFS) and distant recurrence-free survival rates (DRFS) were significantly lower in the high-risk group (73.9% and 75.9%, respectively) and the TNBC group (73.0% and 76.5%, respectively), than the low\/moderate-risk group (86.1% and 87.7%, respectively) (P\u2009<\u2009.0001).<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n This study is in line with earlier observations showing that HR+, HER2\u2013 is the most common subtype, accounting for over 70% of all BC cases. The size of the monarchE-like high-risk group aligns with previous evidence from large US cohort studies. We observed that the proportion of TNBC among all EBC patients showed a decreasing trend between 2010-2019, consistent with earlier reports. The 5-year IDFS and DRFS rates of high-risk patients observed in this study are in line with the evidence from a large US cohort study, however, slightly lower IDFS and DRFS rates at 5 years for the low\/moderate-risk group were observed here.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n About 13.0% of the HR+, HER2\u2013 EBC patient population has a high risk of recurrence and would likely benefit from novel treatment strategies targeted for patients with a high risk of recurrence.<\/jats:p>\n <\/jats:sec>","DOI":"10.36469\/001c.137277","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:40:36Z","timestamp":1748004036000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":4,"title":["Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data"],"prefix":"10.36469","volume":"12","author":[{"given":"Heidi","family":"Loponen","sequence":"first","affiliation":[{"name":"MedEngine Oy, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"MedEngine Oy, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Mehkri","sequence":"additional","affiliation":[{"name":"MedEngine DK Aps, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Torstensson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}],"name":"Eli Lilly Sweden Ab, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Emde","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Ylisaukko-oja","sequence":"additional","affiliation":[{"name":"MedEngine Oy, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"F. Cardoso","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"suppl 5","key":"ref2","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"E. Senkus","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"ref3","article-title":"NCCN Guidelines\u2013Breast Cancer","author":"National Comprehensive Cancer Network","year":"2022","journal-title":"NCCN"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"N. Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database","volume":"25","author":"K. T. Hwang","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10001","key":"ref6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-017-4550-8","article-title":"21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28\/NRG Oncology","volume":"168","author":"E. P. Mamounas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","article-title":"Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer","volume":"16","author":"J. Richman","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"ref9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results From the International Breast Cancer Study Group Trials I to V","volume":"34","author":"M. Colleoni","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"ref10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/1055-9965.EPI-11-1089","article-title":"Hazard of recurrence among women after primary breast cancer treatment\u2014a 10-year follow-up using data from SEER-Medicare","volume":"21","author":"L. Cheng","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref11","article-title":"Breast cancer","author":"World Health Organization","year":"2021"},{"issue":"34","key":"ref12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"S. R. D. Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"ref13","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"A. N. J. Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13058-019-1115-2","article-title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","volume":"21","author":"S.K.L. Chia","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"suppl 4","key":"ref15","doi-asserted-by":"publisher","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS20-GS1-02","article-title":"Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2\u2013negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): first results from PENELOPE-B","volume":"81","author":"S. Loibl","year":"2021","journal-title":"Cancer Res"},{"issue":"16","key":"ref16","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-19-3387","article-title":"A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2\u2212 primary breast cancer","volume":"26","author":"J. F. R. Robertson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref17","article-title":"Verzenios","author":"EMA","year":"2018","journal-title":"European Medicines Agency"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2\u2013negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"S. R. D. Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"N. Harbeck","year":"2021","journal-title":"Ann Oncol"},{"issue":"21","key":"ref20","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2\u2013negative early breast cancer","volume":"18","author":"K. M. Sheffield","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"e0264637","DOI":"10.1371\/journal.pone.0264637","article-title":"Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics","volume":"17","author":"D. R. Nelson","year":"2022","journal-title":"PloS One"},{"issue":"3","key":"ref22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H. Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"L. Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"20","key":"ref24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"W. D. Foulkes","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"ref25","doi-asserted-by":"publisher","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","article-title":"Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race\/Ethnicity, Poverty, and State","volume":"107","author":"B. A. Kohler","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"29","key":"ref26","first-page":"53","article-title":"Triple negative breast cancer: 10-year survival update of the applied treatment strategy in Kuwait","volume":"1","author":"S. Fayaz","year":"2019","journal-title":"Gulf J Oncolog"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BCTT.S69309","article-title":"Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy","volume":"6","author":"Y. Bayoumi","year":"2014","journal-title":"Breast Cancer Dove Med Press"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clon.2018.09.006","article-title":"Outcomes for patients with non-metastatic triple-negative breast cancer in New Zealand","volume":"31","author":"M. James","year":"2019","journal-title":"Clin Oncol R Coll Radiol G B"},{"issue":"4","key":"ref29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.4143\/crt.2015.456","article-title":"Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment","volume":"48","author":"E. Jwa","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"4","key":"ref30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/02841860802059259","article-title":"The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise","volume":"47","author":"S. M\u00f8ller","year":"2008","journal-title":"Acta Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/CLEP.S99457","article-title":"Danish Breast Cancer Cooperative Group","volume":"8","author":"P. Christiansen","year":"2016","journal-title":"Clin Epidemiol"},{"key":"ref32","series-title":"AJCC Cancer Staging Manual","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/978-3-319-40618-3_48","article-title":"Breast","author":"G. N. Hortobagyi","year":"2017"},{"key":"ref33","article-title":"Denmark fact sheet","author":"Globocan 2020"},{"issue":"15","key":"ref34","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for Standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"C. A. Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref35","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/ijc.28222","article-title":"Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark","volume":"133","author":"W. F. Anderson","year":"2013","journal-title":"Int J Cancer J Int Cancer"},{"key":"ref36","article-title":"SEER Female Breast Cancer Subtypes - Cancer Stat Facts","journal-title":"SEER"},{"issue":"17","key":"ref37","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast Cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"S. \u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"ref38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/jpm12030382","article-title":"Feasibility of adjuvant treatment with abemaciclib\u2014real-world data from a large German breast center","volume":"12","author":"D. Dannehl","year":"2022","journal-title":"J Pers Med"},{"key":"ref39","first-page":"S17","article-title":"P047: Real-world study on HR+, HER2\u2212, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns","volume":"56S1","author":"X. Pivot","year":"2021","journal-title":"The Breast"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/02841860802056594","article-title":"Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme","volume":"47","author":"P. Christiansen","year":"2008","journal-title":"Acta Oncol Stockh Swed"},{"issue":"7","key":"ref41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1023\/a:1008928204121","article-title":"Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark","volume":"11","author":"K. Rostgaard","year":"2000","journal-title":"Cancer Causes Control CCC"},{"key":"ref42","article-title":"DBCG Kvalitetsdatabase for Brystkr\u00e6ft National \u00e5rsrapport 2021","author":"Danish Breast Cancer Group","year":"2021"},{"issue":"9","key":"ref43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/0284186X.2017.1327720","article-title":"Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study","volume":"56","author":"D. P. Cronin-Fenton","year":"2017","journal-title":"Acta Oncol"},{"key":"ref44","article-title":"Nordcan 2.0"},{"issue":"3","key":"ref45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02841860310000737","article-title":"Validity and representativity in the Danish Breast Cancer Cooperative Group","volume":"42","author":"A. R. Jensen","year":"2003","journal-title":"Acta Oncol"},{"issue":"3","key":"ref46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5306\/wjco.v5.i3.465","article-title":"Challenges to the early diagnosis and treatment of breast cancer in developing countries","volume":"5","author":"K. Unger-Salda\u00f1a","year":"2014","journal-title":"World J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: Decade report (2005-2015)","volume":"39","author":"F. Cardoso","year":"2018","journal-title":"Breast Edinb Scotl"},{"issue":"5","key":"ref48","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US Incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"N. Howlader","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"8","key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13813","article-title":"Real-world clinical outcomes in biological subgroups of breast cancer in the hospital district of southwest Finland","volume":"26","author":"H. Teerenhovi","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"ref50","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/j.clbc.2020.11.012","article-title":"Real-world evidence of diagnostic testing and treatment patterns in US patients with breast cancer with implications for treatment biomarkers from RNA sequencing data","volume":"21","author":"L. E. Fernandes","year":"2021","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/137277-size-and-treatment-outcomes-of-hr-her2-early-breast-cancer-population-with-high-risk-of-recurrence-a-real-world-cohort-study-with-danish-breast-ca","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:54:39Z","timestamp":1765914879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/137277-size-and-treatment-outcomes-of-hr-her2-early-breast-cancer-population-with-high-risk-of-recurrence-a-real-world-cohort-study-with-danish-breast-ca"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.137277","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}